CME Group Inc. (CME) Stock: Price, Forecast & Analyst Target
CME Group Inc. (CME) — MoonshotScore 97/100 (Exceptional band), calculated Nov 18, 2026. Price $310.25 (-0.42%), as of the Nov 18, 2026 trading session; market cap $111B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
CME Group Inc. · CME · NASDAQ · Financial Services · Financial - Data & Stock Exchanges
Research dated 2026-09-12: CME Group runs derivatives marketplaces and the clearing infrastructure behind them, selling execution, clearing and market data across rates, equity indexes, currencies and commodities. Clearing and transaction fees, rather than stock listings or data alone, are the economic core. Whether that broad contract franchise can sustain activity and cash generation after the latest sequential retreat determines whether its unusually profitable economics endure.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · CME Group (CME)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, though the balance sheet and growth are only decent; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 3, 2027
- Altman Z 0.61 · Piotroski F 6
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 97 | Exceptional | |
| 95 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $310.25 | |
| Change on the day | -0.42% | |
| 52-week range | $218.31–$329.16 | |
| Market capitalisation | $111B | — |
| Price / earnings (trailing) | 25.41 | |
| Shares traded on the day | 2.01M | |
| Beta (volatility vs the S&P 500) | 0.27 |
Why CME Group scores 97
Share price, last 12 months +9.8%
$277.28 $304.52
What the price assumes
10.2% a year of free-cash-flow growth for ten years is what a $109.00B market value ( snapshot) asks for.
The growth the price implies sits inside what the business has recently delivered, so the valuation leans on that record continuing. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $4.33B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 8 of the last 12 reports (2024–2026); the stock still fell the next session after 1 of those beats. Average first-session move: 2.0% either way.
- +1.7%Feb ’24
- -2.0%Apr ’24
- +1.0%Jul ’24
- +1.6%Oct ’24
- +3.5%Feb ’25
- -0.9%Apr ’25
- +0.9%Jul ’25
- +0.1%Oct ’25
- +1.5%Feb ’26
- +0.4%Apr ’26
- +7.1%Jul ’26
- +3.6%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +3.6% | -0.4% | |
| Beat | Beat | +7.1% | +11.8% | |
| In line | In line | +0.4% | +1.0% | |
| In line | In line | +1.5% | +3.2% | |
| Beat | In line | +0.1% | -2.6% | |
| Beat | In line | +0.9% | +1.1% | |
| In line | In line | -0.9% | +4.3% | |
| Beat | In line | +3.5% | +2.7% | |
| In line | In line | +1.6% | +0.5% | |
| Beat | In line | +1.0% | -1.9% | |
| Beat | In line | -2.0% | -4.0% | |
| Beat | In line | +1.7% | +5.1% |
Beats have usually been rewarded — 7 of 8 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “cross margining”, “ficc cross”, “interest rate”, “margining program” — none of them came up in Q2 FY2026.
- Gone quiet: “perpetual futures”, “compute futures”, “funding rate”, “prediction markets” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 8.2 to 4.1 per 1,000 words, and confident words such as “record” and “strong” rose from 3.1 to 6.4.
Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.
Our track record on this stock
Since the score went from 71 to 97 while the share price moved +11.1% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — |
None of the 3 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 41% of 37 rate it a buy; the average target sits +3.7% from the price of $310.25.
- Last 90 days: 1 upgrade and 1 downgrade among 14 rating actions.
- Our signals: Exceptional band; strongest pillar Business Quality (99), weakest Growth Durability (61).
Our signals are more constructive than the crowd, led by Business Quality.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for CME Group (CME): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is CME Group (CME), and what does it report?
Short answer · as of
CME operates marketplaces for futures and options across interest rates, equity indexes, foreign exchange, agriculture, energy and metals.
Research dated 2026-09-12.
Its customers include professional traders, financial institutions, corporations, producers, governments, central banks and individual investors; its clearinghouse also verifies, settles and guarantees contracts.
Calling CME a data and stock-exchange company gives the wrong unit of demand. Reported revenue is led by fees for trades and clearing, with market data and other services contributing smaller pools, so the income statement principally tracks use of derivatives markets and their post-trade infrastructure. The disclosed liquidity balance consists of cash and short-term investments rather than a long-term investment portfolio.
What do the latest results show for CME Group (CME)?
Research dated 2026-09-12.
Revenue, operating profit, net income and operating cash flow all retreated from the immediately preceding period. Against the comparable year-earlier period, revenue and net income advanced while operating profit and cash flow eased, making the latest result a sequential cooling rather than a clean reversal of the annual growth pattern. Reported revenue and earnings still exceeded market expectations.
The fee mix identifies the transmission channel without explaining the fluctuation itself. Because clearing and transaction fees dominate, changes in the use of CME contracts have far more leverage on sales than market data or other revenue, while the annual series continues to show rising revenue and net income.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.74B Oct 21, 2026
- Latest report · revenue estimate
- $1.71B Oct 21, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 21, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 21, 2026 | $1.74B | $1.71B | $3.0200 | $2.9900 |
| Jul 22, 2026 | $1.71B | $1.68B | $2.9900 | $2.9100 |
| Apr 22, 2026 | $1.88B | $1.87B | $3.3600 | $3.3400 |
| Feb 4, 2026 | $1.65B | $1.65B | $2.7700 | $2.7500 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $1.54B | $908M | $2.49 (diluted) |
| Q4 FY2025 | $1.65B | $1.18B | $3.24 (diluted) |
| Q1 FY2026 | $1.88B | $1.15B | $3.18 (diluted) |
| Q2 FY2026 | $1.71B | $1.04B | $2.88 (diluted) |
What are the financial strengths and risks for CME Group (CME)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash generation is a core strength: operating cash flow has remained far above capital spending, annual revenue and net income have advanced throughout the reported series, and trailing margins remain exceptionally high.
Cash and short-term investments do not fully cover debt, liquidity ratios sit near parity, and cash has moved sharply between periods before finishing below the opening level of the displayed window. CME’s specific financial exposure is contraction in trading and hedging activity across its contracts: because transaction and clearing fees dominate, lower use would reach the main revenue pool directly. The clearinghouse guarantee function also makes reliable settlement and risk control central to the franchise.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.61 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 25.41 runs well above the Financial Services sector’s ~17.80x, leaving little room for a miss.
What should you watch next at CME Group (CME)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-12.
The scheduled earnings release will test whether the sequential cooling was temporary. Total revenue, operating profit and operating cash flow need to be read together and set against the direction of the clearing and transaction fee base; renewed growth would restore momentum, while continued broad decline would weaken the longer upward pattern even if reported results clear expectations.
Consensus projections embed continuing gains in revenue and earnings across the forecast horizon. Cash deserves a separate check: stronger cash generation without further erosion in the cash balance would ease the net-debt concern, while weaker cash flow coupled with a wider cash-to-debt gap would make the latest pullback more consequential.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does CME Group compare with its peers?
Short answer
CME Group's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
CME differs from a conventional equities venue because its franchise is built around futures and options spanning rates, indexes, currencies and physical commodities, then extends into clearing and data. That breadth gives customers common risk-transfer infrastructure across distinct exposures; it does not make CME a simple proxy for stock trading.
Economically, the company resembles scalable market infrastructure more than a standalone data vendor: transaction and clearing fees dominate, margins are high, and capital spending is small beside operating cash flow. Its earnings and sales valuation therefore has to be considered in the context of an integrated venue, clearinghouse and data model rather than compared mechanically with businesses selling only listings, execution or feeds.
| Company | Price | Market value | Score |
|---|---|---|---|
| CME Group (CME) — this page | $310.25 | $111B | 97 |
| $316.67 Nov 18, 2026 | $11.2B | 95 5-pillar Nov 18, 2026 | |
| $237.70 Nov 18, 2026 | $8.82B | 95 5-pillar Nov 18, 2026 | |
| $446.38 Nov 18, 2026 | $129B | 91 5-pillar Nov 18, 2026 | |
| $481.29 Nov 18, 2026 | $83.0B | 90 5-pillar Nov 18, 2026 | |
| $636.90 Nov 18, 2026 | $45.5B | 89 5-pillar Nov 18, 2026 | |
| $171.81 Nov 18, 2026 | $96.0B | 87 5-pillar Nov 18, 2026 | |
| $105.72 Nov 18, 2026 | $58.7B | 87 5-pillar Nov 18, 2026 | |
| $162.06 Nov 18, 2026 | $113B | 78 5-pillar Nov 18, 2026 | |
| $38.31 Nov 18, 2026 | $359M | 71 5-pillar Nov 18, 2026 | |
| $87.31 Nov 18, 2026 | $106B | 69 5-pillar Nov 18, 2026 | |
| $9.68 Nov 18, 2026 | $117B | 54 5-pillar Nov 18, 2026 | |
| $34.89 Nov 18, 2026 | $125B | 52 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $227.00 – $367.00
- Consensus target
- $317.91
- Median target
- $330.00
Consensus record · Captured .
Measured against a quoted price of $310.25 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 9, 2026
- Transactions
- 88
- Identified insiders
- 29
- Purchases
- 3
- Sales
- 8
- Other transactions
- 77
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CME in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Baupost Group | Seth Klarman | Q3 2026 | 3.56% | $179.57M | Added +10.7% shares |
| Viking Global | Andreas Halvorsen | Q3 2026 | 0% | $0 | Sold out (was $33.78M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
CME Group Financial Services Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do CME clearing and transaction fees matter more than its market data sales?
Clearing and transaction fees are the dominant revenue stream, making contract use the main route through which customer activity reaches reported sales. Market data adds a smaller revenue pool around the trading and clearing network.
How do CME interest-rate and commodity contracts feed revenue?
Customers use these futures and options to trade or transfer risk, creating transaction-processing and clearing fees for CME. The same activity also supports demand for its market data products, both current and historical.
What does CME’s clearinghouse add beyond trade matching?
The clearinghouse verifies, settles and guarantees futures, options and cleared swaps while providing risk-mitigation services. CME therefore participates in post-trade risk infrastructure as well as operating the trading venues.
Did CME’s latest sequential slowdown end its longer growth pattern?
The latest period cooled from the immediately preceding result, but revenue and net income remained above the comparable year-earlier period and reported results exceeded expectations. The annual series still shows rising revenue and net income.
What is the CME stock price today?
The last price recorded for CME Group Inc. (CME), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CME price target?
The analyst consensus price target for CME Group Inc. (CME), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold CME
Funds in our ETF coverage that list CME among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Invesco Bloomberg Financial Data Providers ETF (FDIQ) | 5.52% | |
| Invesco S&P 500 Equal Weight Financials ETF (RSPF) | 1.64% | |
| Global X - Adaptive U.S. Factor ETF (AUSF) | 1.64% |
